An In Vitro Pilot Study Comparing the Novel HemoClear Gravity-Driven Microfiltration Cell Salvage System with the Conventional Centrifugal XTRA™ Autotransfusion Device
Open Access
- 8 September 2020
- journal article
- research article
- Published by Hindawi Limited in Anesthesiology Research and Practice
- Vol. 2020, 1-10
Abstract
Background. In 2013, the World Health Organization reported a shortage of 17 million red blood cell units, a number that remains growing. Acts to relieve this shortage have primarily focused on allogeneic blood collection. Nevertheless, autologous transfusion can partially alleviate the current pressure and dependence on blood banking systems. To achieve this, current gold standard autotransfusion devices should be complemented with widely available, cost-efficient, and time-efficient devices. The novel HemoClear cell salvage device (HemoClear BV, Zwolle, Netherlands), a gravity-driven microfilter, potentially is widely employable. We evaluated its performance in the cardiac postoperative setting compared to the centrifugal XTRA (TM) autotransfusion device.Methods. In a split-unit study (n = 18), shed blood collected 18 hours after cardiothoracic surgery was divided into two equal volumes. One-half was processed by the XTRA (TM) device and the other with the HemoClear blood separation system. In this paired set-up, equal washing volumes were used for both methods. Washing effectivity and cellular recovery were determined by measuring of complete blood count, free hemoglobin, complement C3, complement C4, and D-dimer in both concentrate as filtrate. Also, processing times and volumes were evaluated.Results. The HemoClear and XTRA (TM) devices showed equal effectiveness in concentrating erythrocytes and leucocytes. Both methods reduced complement C3, complement C4, and D-dimer by >= 90%. The centrifugal device reduced solutes more significantly by up to 99%. Free hemoglobin load was reduced to 12.9% and 15.5% by the XTRA (TM) and HemoClear, respectively.Conclusion. The HemoClear device effectively produced washed concentrated red blood cells comparably to the conventional centrifugal XTRA (TM) autotransfusion device. Although the centrifugal XTRA (TM) device achieved a significantly higher reduction in contaminants, the HemoClear device achieved acceptable blood quality and seems promising in settings where gold standard cell savers are unaffordable or unpractical.Keywords
This publication has 26 references indexed in Scilit:
- Intraoperative cell salvage is associated with reduced postoperative blood loss and transfusion requirements in cardiac surgery: a cohort studyTransfusion, 2013
- Evaluating the impact and use of Transparent Reporting of Evaluations with Non-randomised Designs (TREND) reporting guidelinesBMJ Open, 2012
- Drug, Devices, Technologies, and Techniques for Blood Management in Minimally Invasive and Conventional Cardiothoracic Surgery a Consensus Statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2012
- Washing and filtering of cell‐salvaged blood – does it make autotransfusion safer?Transfusion Alternatives in Transfusion Medicine, 2012
- 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice GuidelinesThe Annals of Thoracic Surgery, 2011
- Cell salvage as part of a blood conservation strategy in anaesthesiaBritish Journal of Anaesthesia, 2010
- Cell salvage for minimising perioperative allogeneic blood transfusion2010
- The Cardiotomy TrialCirculation, 2007
- Red cell hemolysis during processing and storageAsian Journal of Transfusion Science, 2007
- Improving the Reporting Quality of Nonrandomized Evaluations of Behavioral and Public Health Interventions: The TREND StatementAmerican Journal of Public Health, 2004